GET THE APP

Renal Denervation Icarus's Flight? | Abstract
Journal of Medical Diagnostic Methods

Journal of Medical Diagnostic Methods
Open Access

ISSN: 2168-9784

Abstract

Renal Denervation Icarus's Flight?

Grzegorz Marek Karwacki

Since its introduction in 2008 Renal Denervation (RDN) has garnered enthusiasts among physicians, patients and the medical device industry. In December 2013 a research and consulting firm predicted a growth of the global renal denervation market in the next 6 years from approximately 3,000 procedures in 2012 up to nearly 40,000 by 2019 (representing a value of over $170 million). Even though the optimism was toned down D??er 5 years of trial applications of RDN (initial expectations mentioned a market on the order of a billion dollars by 2020), the hype surrounding this invasive therapy method for patients with treatment-resistant hypertension was still on the rise. ?Ls all changed in January 2014 when Medtronic announced that its pivotal SYMPLICITY HTN-3 trial failed to meet its primary efficacy endpoint.

Published Date: 2021-01-30; Received Date: 2021-01-13

Top